Zimmer Biomet Holdings, Inc.

ZBH Healthcare Medical Devices

Zimmer Biomet Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.2 billion, up 7.20% from fiscal 2024. In the quarter to June 2026, revenue grew 4.80%, EPS grew 33.8%, free cash flow grew 13.1% and total debt fell 1.23%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five.

95.06 0.68 +0.72%
Market cap
$18.0B
P/E
23.0×
Fwd P/E
17.7×
Dividend yield
1.01%
F-score
6/9
Altman Z
2.38
Beneish M
−2.59
Dividend safety
72/100
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
25.19 23.74 24.72 115.71 63.91 0.00 26.37 0.00 13.24 67.33
Piotroski F-Score
6 6 8 5 7 3 7 5 6 5
P/S ratio
2.16 2.79 3.43 3.84 3.77 5.05 3.73 2.58 3.12 2.62
Altman Z-Score
2.38 2.86 3.01 2.97 2.53 2.49 2.59 1.94 2.00 1.64
Altman Z″-Score (non-manufacturers)
3.96 4.25 3.96 3.74 3.31 3.10 3.09 2.76 2.70 2.40
P/FCF ratio
16.53 27.41 28.94 30.60 26.30 61.12 36.76 15.66 22.33 18.21
Beneish M-Score
(2.59) (2.59) (2.54) (2.62) (2.72) (2.57) (2.43) (3.07) (2.51) (2.59)
P/Operating CF
34.41 42.37 43.06 109.25 76.21 104.55 70.41 54.00 60.36 31.99
Dividend Safety Score
72 — — — — — — — — —
P/B ratio
1.40 1.72 2.03 2.22 2.03 2.54 2.41 1.82 2.07 2.07
Price to Tangible BV
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Sales
3.00 3.53 4.15 4.61 4.75 6.25 4.69 3.64 4.35 4.00
EV/EBITDA
11.28 11.89 13.76 16.71 17.87 25.79 16.90 14.06 15.47 16.22
EV/Operating CF
14.57 18.10 19.40 23.59 23.09 35.60 23.59 16.53 21.45 18.79
EV/FCF
22.96 34.67 35.05 36.70 33.14 75.57 46.13 22.08 31.15 27.83
Quick Ratio
0.89 0.82 0.65 0.75 0.47 0.88 0.58 0.75 0.67 0.94
Current Ratio
1.98 1.91 1.61 1.88 1.41 1.99 1.37 1.83 1.49 1.96
Net Debt/EBITDA
3.16 2.49 2.40 2.78 3.69 4.93 3.43 4.09 4.38 5.61
Debt/Assets
32.56% 29.04% 26.83% 27.04% 30.14% 33.28% 33.37% 37.05% 38.99% 42.13%
Debt/Equity
0.59 0.50 0.46 0.47 0.56 0.67 0.66 0.79 0.86 1.16
Asset Turnover
0.37 0.36 0.35 0.31 0.29 0.25 0.33 0.32 0.30 0.28
Operating CF/Net income
2.41 1.66 1.54 5.86 3.50 (7.74) 1.40 (4.61) 0.87 5.34
Capex/Depreciation
(0.53) (0.60) (0.74) (0.39) (0.45) (0.26) (0.67) (0.22) (0.35) (0.50)
Interest Coverage
3.75 5.90 6.35 4.23 4.13 0.39 5.01 0.12 2.46 2.31
ROE
5.60% 7.24% 8.35% 1.87% 3.23% (1.13%) 9.56% (3.30%) 16.95% 3.13%
ROA
3.17% 4.22% 4.81% 1.04% 1.68% (0.57%) 4.64% (1.51%) 6.88% 1.14%
ROIC
3.50% 4.43% 4.48% 2.51% 2.78% 0.27% 3.56% 0.11% 2.34% 2.53%
Return on Tangible Assets
14.87% 21.17% 26.86% 5.87% 12.34% (3.04%) 33.68% (9.43%) 51.33% 7.08%
Average Days of Receivables
75.58 70.38 71.20 72.66 67.34 86.53 62.37 58.70 72.23 76.37
Research and Development Expense of Revenue
5.57% 5.70% 6.20% 5.85% 6.38% 5.27% 5.63% 4.94% 4.74% 4.77%
Selling, General and Administrative Expense of Revenue
39.57% 38.16% 38.39% 39.79% 41.65% 44.27% 41.89% 42.60% 39.79% 38.40%
Intangible Assets out of Total Assets
0.64 0.63 0.64 0.65 0.62 0.67 0.68 0.72 0.73 0.73
Share Based Compensation of Revenue
1.10% 1.32% 1.35% 1.51% 1.11% 1.20% 1.06% 0.83% 0.69% 0.75%
Graham Net Nets
(0.30) (0.20) (0.17) (0.17) (0.23) (0.23) (0.25) (0.41) (0.40) (0.62)
Graham Number
71.79 78.43 81.31 37.69 51.35 0.00 86.55 0.00 109.09 40.26
Earnings Yield
3.97% 4.21% 4.04% 0.86% 1.56% (0.45%) 3.79% (1.84%) 7.56% 1.49%
Free Cash Flow Yield
6.05% 3.65% 3.46% 3.27% 3.80% 1.64% 2.72% 6.38% 4.48% 5.49%
Revenue per Share
41.57 37.81 35.43 33.11 32.73 29.60 38.92 38.98 38.65 38.34
Operating CF per Share
8.57 7.38 7.58 6.47 6.73 5.20 7.73 8.59 7.84 8.16
Capex per Share
(2.92) (2.94) (3.38) (2.27) (2.04) (1.79) (3.51) (2.16) (2.44) (2.65)
Free Cash Flow per Share
5.66 4.44 4.19 4.20 4.69 3.40 4.22 6.43 5.40 5.51
Cash per Share
2.99 2.59 1.99 1.79 1.81 3.87 3.01 2.67 2.60 3.17
Shareholders Equity per Share
64.17 61.43 59.84 57.38 60.72 58.93 60.42 55.41 58.13 48.35
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
64.17 61.43 59.84 57.38 60.72 58.93 60.42 55.41 58.13 48.35
Free Cash Flow
1,119.70 902.30 875.40 880.30 978.70 704.30 865.20 1,308.40 1,089.30 1,102.00
Working Capital
2,536.20 2,220.60 1,752.10 2,069.10 1,417.10 2,526.40 1,282.40 2,006.10 1,495.10 2,282.10
Capital Expenditures
(577.40) (597.10) (706.20) (475.90) (425.60) (371.30) (720.60) (439.00) (493.00) (530.20)
Net Current Asset Value
(5,266.10) (4,217.60) (4,399.20) (4,611.70) (5,905.00) (7,135.00) (7,522.00) (8,423.30) (9,713.70) (12,350.90)
EV/EBIT
22.52 21.10 24.02 45.96 37.68 460.79 32.89 854.69 42.46 37.35
Capex to Sales
0.07 0.08 0.10 0.07 0.06 0.06 0.09 0.06 0.06 0.07
Price to Operating Income
16.21 16.69 19.83 38.31 29.91 372.65 26.20 606.29 30.43 24.44
Other line items
Depreciation/Fixed assets
0.50 0.49 0.46 0.65 0.52 0.68 0.52 1.00 0.68 0.53
Cash ROIC
5.38% 4.70% 4.69% 4.86% 4.87% 3.33% 4.07% 6.30% 4.86% 5.11%
Accounts Receivable Turnover
5.17 5.25 5.24 5.26 5.03 4.35 6.05 5.63 4.96 5.03
Accounts Payable Turnover
10.02 7.24 5.45 6.11 6.16 4.99 5.90 6.56 6.14 7.34
Inventory Turnover
1.10 0.95 0.92 0.94 0.85 0.75 0.97 1.05 1.06 1.13
Average Days of Payables
44.35 32.42 71.92 64.00 57.07 66.03 64.96 58.25 56.51 55.86
Days of Inventory on Hand
334.66 372.35 417.79 388.08 399.93 490.33 386.45 362.53 353.95 300.27
Average Receivables
1,592.55 1,461.55 1,411.95 1,320.55 1,356.15 1,408.30 1,319.85 1,409.95 1,574.25 1,525.45
Average Payables
248.80 302.60 382.35 330.30 318.25 365.45 381.75 346.40 347.35 324.65
Average Inventory
2,260.85 2,310.25 2,266.20 2,147.60 2,299.35 2,417.85 2,320.75 2,162.40 2,013.85 2,106.75
Average Assets
22,228.50 21,431.10 21,281.45 22,261.20 23,937.05 24,528.20 24,382.75 25,070.40 26,349.20 26,922.50
Average Common Equity
12,591.00 12,482.20 12,257.60 12,346.70 12,432.90 12,296.10 11,834.45 11,505.80 10,702.70 9,779.65

Fold the line items

Columns are period end dates